IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group

Source: Melanoma News Today, April 2017

Prima Biomed, an Australian biotechnology company developing immunotherapies for cancer and autoimmune diseases, announced it has received approval for the third cohort of its Phase 1 melanoma trial (NCT02676869), TACTI-mel.

The trial is being conducted in Australia and is actively recruiting patients for its third group, which will include a total of six patients with unresectable or metastatic melanoma.

This is an interventional study with the primary objective of determining the safety, tolerability, and recommended Phase 2 dose of a new drug called IMP321, combined with Keytruda (pembrolizumab) in patients with stage 3 or 4 melanoma.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories